Exscientia (NASDAQ:EXAI) Hits New 12-Month Low at $4.13

Exscientia plc (NASDAQ:EXAI)’s share price hit a new 52-week low during trading on Wednesday . The company traded as low as $4.13 and last traded at $4.16, with a volume of 213422 shares traded. The stock had previously closed at $4.38.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on EXAI shares. Morgan Stanley reissued an “equal weight” rating and issued a $7.00 price target on shares of Exscientia in a research note on Monday. Bank of America downgraded shares of Exscientia from a “buy” rating to a “neutral” rating and reduced their price target for the company from $11.00 to $9.00 in a research note on Friday, January 5th.

Exscientia Trading Down 5.7 %

The firm has a market cap of $499.28 million, a price-to-earnings ratio of -2.96 and a beta of 0.78. The company’s 50 day simple moving average is $5.73 and its 200 day simple moving average is $5.85. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.22 and a quick ratio of 6.22.

Exscientia (NASDAQ:EXAI) last posted its quarterly earnings results on Thursday, March 21st. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.02. Exscientia had a negative net margin of 737.10% and a negative return on equity of 36.44%. The company had revenue of $3.10 million during the quarter, compared to analysts’ expectations of $41.63 million. As a group, research analysts expect that Exscientia plc will post -1.76 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Exscientia

A number of institutional investors and hedge funds have recently added to or reduced their stakes in EXAI. Bank of New York Mellon Corp increased its stake in Exscientia by 26.4% in the third quarter. Bank of New York Mellon Corp now owns 155,097 shares of the company’s stock valued at $701,000 after purchasing an additional 32,373 shares during the period. Banque Pictet & Cie SA acquired a new position in shares of Exscientia in the third quarter valued at approximately $1,040,000. Platinum Investment Management Ltd. raised its stake in shares of Exscientia by 10.2% during the third quarter. Platinum Investment Management Ltd. now owns 4,395,058 shares of the company’s stock worth $19,866,000 after purchasing an additional 405,426 shares during the last quarter. Jump Financial LLC acquired a new stake in shares of Exscientia during the third quarter worth $165,000. Finally, Mitsubishi UFJ Trust & Banking Corp grew its position in Exscientia by 6.0% in the 3rd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 203,970 shares of the company’s stock valued at $922,000 after buying an additional 11,570 shares during the last quarter. Hedge funds and other institutional investors own 41.58% of the company’s stock.

Exscientia Company Profile

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.